TuesdayJun 20, 2023 10:15 am

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R) Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in…

Continue Reading

TuesdayJun 20, 2023 9:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Shares anticipated 0-200% Revenue Growth for 2023; Reports Highest Monthly Increase in New Clients during month of March

Fr8Tech’s management recently shared its updated 2023 revenue guidance of $25-30 million, representing as much as nearly 20% growth from the previous year’s full-year revenue The growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new client sign-ups since the launch of the Fr8App platform Following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance, the company showed that the price would need to show 11x growth on the closing price of March 28, 2023 to meet with third party forecasts…

Continue Reading

ThursdayJun 15, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1 Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18) These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease,…

Continue Reading

WednesdayJun 14, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer

The positive data from the Acclaim-1 Phase 1 portion of the Phase 1/2 clinical trial has been published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, which took place in Chicago, IL and online June 2 – 6, 2023 Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA(R) in combination with Tagrisso(R) The Phase 2 expansion portion of the study is expected to enroll approximately 66 patients – half of which will have only received Tagrisso(R) and the other half receiving Tagrisso(R) and chemotherapy The global lung cancer treatment market is expected to…

Continue Reading

FridayJun 09, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical…

Continue Reading

WednesdayJun 07, 2023 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) CEO Believes in Importance of Adopting Quantum Mindset Amid Today’s Complex Business Environment

Quantum computing can be a tool to help enterprises navigate the ongoing disruption and complexity of today’s business world Quantum adoption is expected to grow substantially over next 15-30 years, practical quantum solutions are already here, and demand for quantum-ready talent is rapidly accelerating Governments around the world have developed quantum adoption and investment strategies As businesses encounter challenging computational problems that classical computers are ill-equipped to solve efficiently, or at all, the value of quantum computing is becoming increasingly apparent. Quantum can be used to tackle data-intensive computations in the areas of logistics, artificial intelligence, materials sciences, drug discovery,…

Continue Reading

MondayJun 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Animal Study Showing Its Patented DehydraTECH(TM) Technology Significantly Enhances Oral Delivery of Estradiol; Raises $2 Million in Gross Proceeds from Public Offering

Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone Estrone is a type of estrogen that can be reversibly made from estradiol in certain tissues within the female body The study HOR-A22-1 also revealed that DehydraTECH resulted in 1,500% and 12,500% higher exposure to estradiol and estrone over time, respectively, compared to the control Lexaria…

Continue Reading

FridayJun 02, 2023 9:45 am

Mullen Automotive Inc. (NASDAQ: MULN) Inks Class 3 Truck PO, Purchase Agreement in Continued Upward Momentum

MULN received an order for one thousand class 3 trucks from its dealer partner, Randy Marion Automotive The company is excited about entering the next phase of its commercial launch with the Mullen THREE Mullen inked a $15 million vehicle purchase agreement with the MGT Lease Company for 250 class 3 cab chassis EV trucks On the heels of several purchase agreements and orders, Mullen Automotive (NASDAQ: MULN) is experiencing impressive momentum as it continues to focus on growing in the electric vehicle space. Most recently, the company received a 1,000-unit purchase order (https://ibn.fm/2tLyU) and announced a $15.7 million vehicle purchase…

Continue Reading

FridayJun 02, 2023 9:15 am

Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment

Gene Therapy's Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga. Click Here for the full article The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex's innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer. The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex's Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account…

Continue Reading

Contact us: (310) 299-1717